Answers are grounded in this paper and cite their sources.
Integrative frameworks that connect scalable clinical phenotypes with molecular mechanisms are needed to resolve disease heterogeneity. We developed and externally evaluated an interpretable gout clinical-subset framework using routine data from 21,235 participants across UK Biobank (UKB; n = 10,599), the multicentre Chinese GoutRe registry ( n = 8617), and MIMIC-IV ( n = 2019). Unsupervised learning on six prespecified routine laboratory variables identified three subsets: C1, a low-burden state with preserved reserve; C2, a urate-metabolic inflammatory state with the greatest recurrence liability and a greater cardiometabolic and hepatic comorbidity burden; and C3, a state characterized by systemic vulnerability and higher mortality. In UKB, death-competing recurrence analysis showed a higher recurrence incidence for C2 versus C1 (subdistribution hazard ratio [sHR] 1.896, 95% CI 1.710–2.101), whereas C3 did not differ from C1 (sHR 0.994, 95% CI 0.887–1.112). A six-variable CRT model reconstructed the locked subset labels using nested 10-fold out-of-fold evaluation in UKB and external application without retraining in GoutRe and MIMIC-IV. One-versus-rest AUCs were 0.965/0.945/0.980 in UKB, 0.906/0.914/0.953 in GoutRe, and 0.912/0.898/0.962 in MIMIC-IV for C1/C2/C3, respectively. Genetic, proteomic, and metabolomic analyses supported distinct urate-inflammatory and systemic-vulnerability axes, although the C3 senescence-related genetic signal was nominal and requires replication. Routine laboratory data can identify gout clinical subsets with distinct molecular profiles and patterns of recurrence and mortality; whether these subsets can guide clinical management requires prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: